Page 12 - Immune Sciences News Today

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.36 and traded as high as $8.71. Alpine Immune Sciences shares last traded at $8.57, with a volume of 181,061 shares. Analyst Ratings Changes Several brokerages […]

Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results... | May 11, 2023

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) will be posting its quarterly earnings results on Wednesday, May 10th. Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last released its quarterly earnings results on Thursday, March 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.14). […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,050,000 shares, a growth of 17.6% from the March 15th total of 892,900 shares. Based on an average daily trading volume, of 84,200 shares, the days-to-cover […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.19 and traded as high as $8.10. Alpine Immune Sciences shares last traded at $8.09, with a volume of 62,603 shares traded. Analyst Upgrades and Downgrades […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Equities research analysts at Wedbush issued their Q1 2024 EPS estimates for Alpine Immune Sciences in a research note issued to investors on Friday, March 24th. Wedbush analyst R. Driscoll anticipates that the biotechnology company will post earnings per share of ($0.23) for the quarter. Wedbush […]

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Oppenheimer issued their Q1 2024 earnings per share estimates for shares of Alpine Immune Sciences in a research note issued to investors on Friday, March 24th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($0.41) per share for the quarter. The […]

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) had its price objective increased by HC Wainwright from $8.00 to $11.00 in a research report report published on Friday morning, The Fly reports. HC Wainwright also issued estimates for Alpine Immune Sciences’ Q2 2023 earnings at ($0.35) EPS and Q3 2023 earnings at ($0.39) EPS. Separately, Morgan […]

23.03.2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for ...

Stock Analysts’ price target changes for Friday, March 24th: AirBoss of America (OTCMKTS:ABSSF) had its price target lowered by TD Securities from C$14.00 to C$11.50. Accolade (NASDAQ:ACCD) had its target price raised by Truist Financial Co. to $17.00. Accenture (NYSE:ACN) had its price target boosted by Citigroup Inc. from $300.00 to $310.00. Citigroup Inc. currently […]